food companies glp-1 Why makers aren't afraid of drugs Crafting product claims in the

Image Credit: zimmytws / Shutterstock In a recent study published in JAMA Network Open , researchers investigated the associations between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and all-cause mortality and recurrence-free survival (RFS) among adult female breast cancer (BC) patients

While once viewed as primarily drugs for treating diabetes, these therapies are now finding new markets, but putting new pressures and challenges for the healthcare system and pharmaceutical companies

Secondly, given the prevalence of conditions such as obesity and overweight, high blood glucose, cholesterol, and triglyceride levels, there was a need to explore alternative and potentially effective interventions beyond traditional medications. In the study, the researchers assigned 120 Lebanese participants (mean age, 17 years) with overweight or obesity to intervention groups receiving either 5 mL, 10 mL or 15 mL of ACV daily or to a control group over a 12-week period

Doctors) and immediately pitches

10.1523/JNEUROSCI.1870-13.2014 638 WrobelL.TopfU.BragoszewskiP.WieseS.SztolsztenerM